SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

LEUPLINENANTONE

TAK·TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 1985. All major depot formulations (1-month, 3-month, 6-month) are on the market globally.
Why 3/10
This is an already-approved, marketed drug with no pending FDA decision, pivotal trial readout, or regulatory catalyst. It is one of many mature products in Takeda's broad commercial portfolio. The defining binary (initial FDA approval) passed decades ago, and all subsequent formulation extensions are also approved and commercialized. No dated binary catalyst exists.
Actionable Insight NEUTRAL

Leuprorelin acetate is a mature, off-patent product for Takeda. Watch for generic erosion in Takeda's Japan and EU revenue disclosures during quarterly earnings, but there is no single binary catalyst for this drug that would move TAK shares. Takeda's next major pipeline catalysts include the Phase 3 readout for zasocitinib and the ongoing commercial launch of ORZEYFUL (oveporexton) and MIMRYLO (rusfertide), which are far more material to the stock.

Price Chart

Loading chart...

Executive Summary

LEUPLINENANTONE is not a single drug but a concatenation of two Takeda brand names (Leuplin in Japan, Enantone in Europe) for the same active ingredient: leuprorelin acetate (leuprolide), a GnRH agonist used to suppress sex hormones in prostate cancer, premenopausal breast cancer, endometriosis, and uterine fibroids. Originally developed through the Takeda-Abbott partnership (TAP) and first FDA-approved in 1985 as Lupron, this is a mature, off-patent product facing generic competition. For Takeda (NYSE: TAK), a diversified global pharma company with a market cap around $60B+, leuprorelin products are a small part of a broad portfolio. There are no upcoming binary catalysts for this drug; Takeda's stock is driven by newer pipeline assets like zasocitinib, ORZEYFUL, and MIMRYLO.

How It Works

Leuprorelin acetate is a synthetic hormone that mimics a natural hormone called GnRH. Initially it causes a temporary surge in sex hormone production (testosterone in men, estrogen in women), but with continued use it shuts down the pituitary gland's signal, dramatically reducing those hormone levels. This chemical castration effect is used to treat hormone-driven cancers like prostate cancer and premenopausal breast cancer, as well as endometriosis and uterine fibroids. It is given as a slow-release injection that can last from 1 to 6 months per dose.

Trial Status

Leuprorelin acetate is a mature, approved drug. It continues to be studied in investigator-sponsored trials exploring new combinations and indications (e.g., neoadjuvant use in prostate cancer with darolutamide), but Takeda has no registrational trials running for this molecule. The active ingredient's patent protection has expired and multiple generic versions are available globally.

The Two-Sided Case

▲ Bull Case3
Leuprorelin acetate remains a standard of care for prostate cancer and other hormone-dependent conditions globally, with the leuprolide acetate market valued at around $2.9-3.1 billion in 2026 and projected to grow at 4.7-6.4% CAGR through 2030.
Takeda's established manufacturing and distribution infrastructure for leuprorelin depot formulations in Japan and Europe provides a steady revenue stream. Takeda is one of the few manufacturers of this complex injectable depot product.
Takeda's overall business showed strong H1 FY2026 results (reported Oct 29, 2026) with revenue up 8.4% AER and net profit up 171.8%, driven in part by the broad product portfolio.
▼ Bear Case3
Generic competition is eroding revenue: leuprolide acetate is off-patent, with multiple generic entrants in major markets including a generic injection launched by Avenacy in 2025. The leuprorelin drugs market faces pricing pressure.
Takeda's leuprorelin products are mature (first approved in 1985) and face declining sales as newer hormone therapies (GnRH antagonists like relugolix, oral therapies) gain share.
Insider selling at Takeda has been heavy in the past 90 days, with 10+ executives selling shares in August-September 2026, including the CEO and President of R&D.

Upcoming Catalysts

  • None for this specific drug. For Takeda broadly: Capital Markets Day on December 11, 2026 in Tokyo; ongoing regulatory reviews for zasocitinib; commercial launch trajectory for ORZEYFUL (oveporexton) and MIMRYLO (rusfertide).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report

Sources · 11

Hover a chip for the title
1 businesswire.com2 takeda.com3 theraradar.com4 adisinsight.springer.com5 hemonc.org6 mordorintelligence.com7 thebusinessresearchcompany.com8 catalystalert.io9 sec.gov10 drugpatentwatch.com11 pmc.ncbi.nlm.nih.gov